BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioCardia, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.90−0.02 (-2.46%)
Close on Oct 19, 2026
- Market cap
- $10.85M
- P/E (TTM)
- –
- Dividend yield
- –
BioCardia, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Agreement [Member] | $477.00K | $1.35M | $1.01M | $132.00K | $528.00K | $343.00K | $90.00K | $59.00K | 100.0% | -64.6% |
| Product [Member] | $0 | $3.00K | $1.00K | $13.00K | $182.00K | $282.00K | $389.00K | $517.00K | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of BioCardia's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.